Purified anti-PIK3R2 Antibody, PIK3R2, W17020A,BioLegend,667001

This clone failed to immunoprecipitate PIK3R2 from MCF-7 lysates. We therefore do not recommend W17020A for this application.This clone failed to stain PIK3R2 from PFA-fixed and methanol permeabilized MCF-7 cells when tested by ICC. We therefore do not recommend W17020A for this application.Due to pockets of high sequence similarity between the immunizing sequence and PIK3R1, this clone may cross-react with PIK3R1.

Host

Rat

Reactivity

Human, Mouse

Application

WB -Quality tested

Platform ID

BAB017147381

BioLegend

Headquarters

8999 BioLegend Way San Diego, CA 92121 United States

Contact

Tel: 1-858-455-9588
Fax: +49 (4131) 7023913

Email:

Product Specifications
Scientific Background

Specifications

NamePurified anti-PIK3R2 Antibody, PIK3R2, W17020A
Cat. No.667001
HostRat
RRIDAB_2801126 (BioLegend Cat. No. 667001)AB_2801127 (BioLegend Cat. No. 667002)
IsotypeRat IgG2b, κ
ReactivityHuman, Mouse
ApplicationWB -Quality tested
ClonalityMonoclonal
Clone NumberW17020A
Concentration0.5 mg/ml
TargetPIK3R2
ImmunogenRecombinant human PIK3R2 (aa 426-621)
PurityThe antibody was purified by affinity chromatography.
FormulationPhosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
StorageThe antibody solution should be stored undiluted between 2°C and 8°C.
Regulatory StatusResearch Use Only

Scientific Background

Phosphoinositide-3-kinase (PI3 kinase) is a lipid kinase that plays a critical role in cell signaling through generation of phosphoinositides at the plasma membrane in response to growth factor and hormone stimulation. Activation of PI3K is essential for cell growth, migration, motility, and survival. PI3K is comprised of a catalytic subunit, p110, that harbors enzymatic activity and a regulatory subunit, p85, that promotes both p110 stability and inhibition of p85. Moreover, p85 recognizes phosphorylated growth factor receptors via 2 SH2 domains that bring the PI3K dimer to the plasma membrane and in closer proximity to its substrate. Two p85 isoforms, p85α and p85β, have been described. Elevated expression of PIK3R2 (p85β) has been described in breast and colon cancers and is associated with increased tumorigenesis.

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.